D6Mm5e Inhibitors
The M1AP protein, essential for meiotic progression, plays a crucial role in mediating key events during gametogenesis. As a regulator of meiosis, M1AP orchestrates intricate signaling pathways and molecular interactions that govern the transition through the meiotic cell cycle. Its activity is tightly controlled through phosphorylation events, interactions with binding partners, and association with crucial kinases. M1AP inhibitors represent a class of chemicals designed to interfere with the function of M1AP, either directly or indirectly. Direct inhibitors, such as Staurosporine and Roscovitine, target specific kinases involved in M1AP activation, hindering essential phosphorylation events and disrupting meiotic progression. Indirect inhibitors, such as PD 98059 and Wortmannin, influence upstream signaling pathways like the MAPK and PI3K/AKT cascades, respectively, impacting M1AP function indirectly. These chemicals act as modulators of critical cellular processes, altering the regulatory landscape and impeding M1AP-mediated meiotic advancement.
The specificity of M1AP inhibitors lies in their precise interference with the molecular mechanisms governing meiosis. By targeting key regulatory elements associated with M1AP, these inhibitors offer valuable tools for unraveling the intricate web of signaling events orchestrating meiotic progression. Understanding the detailed biochemical and cellular effects of M1AP inhibitors provides insights into the fundamental processes regulating gametogenesis, offering potential avenues for further research in reproductive biology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent protein kinase inhibitor, Staurosporine disrupts meiotic progression by inhibiting key kinases associated with M1AP activation. It interferes with critical phosphorylation events, impeding the protein's function in mediating meiotic cell cycle advancement. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
As a cyclin-dependent kinase inhibitor, Roscovitine targets cell cycle regulators involved in meiosis. By preventing phosphorylation events crucial for M1AP activation, it obstructs the protein's function, leading to a disruption in the meiotic cell cycle progression. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
Acting as a GSK-3 inhibitor, SB-216763 disrupts the glycogen synthase kinase pathway, indirectly affecting M1AP function. This inhibition alters downstream signaling pathways, impeding meiotic progression by influencing key regulatory processes associated with M1AP. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor, PD 98059 disrupts the MAPK pathway, influencing M1AP indirectly. By dampening this signaling cascade, the inhibitor alters the phosphorylation status of M1AP, hindering its role in meiotic progression and impeding cell cycle advancement. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibiting phosphatidylinositol 3-kinase (PI3K), Wortmannin disrupts the PI3K/AKT pathway, indirectly affecting M1AP. This interference leads to altered downstream signaling, impacting meiotic progression by modulating key cellular processes associated with M1AP function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor, SP600125 disrupts the JNK signaling pathway, indirectly influencing M1AP. This inhibition alters the phosphorylation events crucial for M1AP activation, hindering its role in meiotic progression and impeding cell cycle advancement. | ||||||
VX-11e | 896720-20-0 | sc-507301 | 10 mg | $180.00 | ||
A histone deacetylase (HDAC) inhibitor, VX-11e disrupts epigenetic regulation associated with M1AP expression. This inhibition leads to altered chromatin structure, affecting the accessibility of key regulatory elements, and ultimately impeding M1AP-mediated meiotic progression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
An inhibitor of phosphatidylinositol 3-kinase (PI3K), LY294002 disrupts the PI3K/AKT pathway, indirectly affecting M1AP. This interference leads to altered downstream signaling, impacting meiotic progression by modulating key cellular processes associated with M1AP function. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
GSK-3 Inhibitor XVI disrupts the glycogen synthase kinase pathway, indirectly affecting M1AP. This interference alters downstream signaling pathways, impeding meiotic progression by influencing key regulatory processes associated with M1AP function. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
A dual mTORC1 and mTORC2 inhibitor, AZD8055 disrupts the mTOR signaling pathway, indirectly influencing M1AP. This inhibition alters the phosphorylation events crucial for M1AP activation, hindering its role in meiotic progression and impeding cell cycle advancement. | ||||||